[HL-A system and blood transfusion].
Anti-HL-A alloimunization has increased in frequency, particularly in patients with acute leukemia, since platelet and leukocyte transfusions have been systematically used for the prevention of hemorrhages and infections during the induction phase of chemotherapy. Although a systematic prevention of anti-HL-A immunization is not yet feasible in most cases, the selection of HL-A compatible donors can restore the efficiency of platelet and leukocyte transfusions even if alloimmunization is very severe. Compatible donors can sometimes be found in the patient's family, but the existence of a panel of HL-A typed blood donors will considerably facilitate the efficiency of the hematological supportive care of patients with leukemia and with bone-marrow aplasia of other origins.
D001782:Blood Donors; D001803:Blood Transfusion; D003601:Cytotoxicity Tests, Immunologic; D006470:Hemorrhage / Q000517:prevention & control; D006649:Histocompatibility Antigens; D006801:Humans; D007106:Immune Sera; D007948:Leukemia, Monocytic, Acute / Q000628:therapy; D007951:Leukemia, Myeloid / Q000628:therapy; D007962:Leukocytes
D006649:Histocompatibility Antigens; D007106:Immune Sera
Systéme HL-A et transfusion sanguine